Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial

Open access
Watanabe, Hirotoshi, Morimoto, Takeshi, Natsuaki, Masahiro, Yamamoto, Ko, Obayashi, Yuki, Ogita, Manabu, Suwa, Satoru, Isawa, Tsuyoshi, Domei, Takenori, Yamaji, Kyohei, Tatsushima, Shojiro, Watanabe, Hiroki, Ohya, Masanobu, Tokuyama, Hideo, Tada, Tomohisa, Sakamoto, Hiroki, Mori, Hiroyoshi, Suzuki, Hiroshi, Nishikura, Tenjin, Wakabayashi, Kohei, Hibi, Kiyoshi, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Morino, Yoshihiro, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, Kimura, Takeshi, STOPDAPT-2 ACS Investigators, Kozuma, Ken, Hanaoka, Keiichi, Tezuka, Saori, Fujino, Yumika, Kato, Risa, Kitamura, Masayo, Tsumori, Miyuki, Hanazawa, Miya, Yamauchi, Misato, Yamazaki, Itsuki, Hirokami, Mitsugu, Makiguchi, Nobuko, Nozaki, Yoichi, Tomita, Hirofumi, Yagi, Masahiro, Komaru, Tatsuya, Higuchi, Motoaki, Isshiki, Takaaki, Kodama, Takahide, Tosaka, Atsushi, Takamisawa, Itaru, Tanaka, Hiroyuki, Hata, Yoshiki, Kato, Ryuichi, Akashi, Yoshihiro, Yumoto, Kazuhiko, Tsukahara, Kengo, Ako, Junya, Onishi, Yuko, Uzui, Hiroyasu, Noda, Toshiyuki, Morishima, Itsuo, Yamada, Minoru, Yoshida, Ruka, Suzuki, Susumu, Maeda, Takuya, Tanigawa, Takashi, Kaitani, Kazuaki, Matsuoka, Shunzo, Akao, Masaharu, Yokomatsu, Takafumi, Inoko, Moriaki, Inada, Tsukasa, Morita, Takashi, Nakazawa, Gaku, Ishihara, Shozo, Kinoshita, Makoto, Kusuyama, Takanori, Togi, Kiyonori, Tamura, Toshihiro, Akasaka, Takashi, Tabuchi, Isao, Kihara, Yasuki, Ueda, Hironori, Katayama, Yusuke, Wakeyama, Takatoshi, Kaneko, Takeo, Wakatsuki, Tetsuzo, Kishi, Koichi, Doi, Masayuki, Okayama, Hideki, Suematsu, Nobuhiro, Inoue, Shujiro, Natsuaki, Masahiro, Tsujita, Kenichi, Sakamoto, Tomohiro, Kurokawa, Hirofumi, Kashima, Katsuro, Uehara, Hiroki·2022·JAMA Cardiology

Abstract

IMPORTANCE: Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS). OBJECTIVE: To test the hypothesis of noninferiority of 1 to 2 months of DAPT compared with 12 months of DAPT for a composite end point of cardiovascular and bleeding events in patients with ACS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized clinical trial enrolled 4169 patients with ACS who underwent successful PCI using cobalt-chromium everolimus-eluting stents at 96 centers in Japan from December 2015 through June 2020. These data were analyzed from June to July 2021. INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular (cardiovascular death, myocardial infarction [MI], any stroke, or definite stent thrombosis) or bleeding (Thrombolysis in MI major or minor bleeding) events at 12 months, with a noninferiority margin of 50% on the hazard ratio (HR) scale. The major secondary end points were cardiovascular and bleeding components of the primary end point. RESULTS: Among 4169 randomized patients, 33 withdrew consent. Of the 4136 included patients, the mean (SD) age was 66.8 (11.9) years, and 856 (21%) were women, 2324 (56%) had ST-segment elevation MI, and 826 (20%) had non-ST-segment elevation MI. A total of 4107 patients (99.3%) completed the 1-year follow-up in June 2021. One to 2 months of DAPT was not noninferior to 12 months of DAPT for the primary end point, which occurred in 65 of 2058 patients (3.2%) in the 1- to 2-month DAPT group and in 58 of 2057 patients (2.8%) in the 12-month DAPT group (absolute difference, 0.37% [95% CI, -0.68% to 1.42%]; HR, 1.14 [95% CI, 0.80-1.62]; P for noninferiority = .06). The major secondary cardiovascular end point occurred in 56 patients (2.8%) in the 1- to 2-month DAPT group and in 38 patients (1.9%) in the 12-month DAPT group (absolute difference, 0.90% [95% CI, -0.02% to 1.82%]; HR, 1.50 [95% CI, 0.99-2.26]). The major secondary bleeding end point occurred in 11 patients (0.5%) in the 1- to 2-month DAPT group and 24 patients (1.2%) in the 12-month DAPT group (absolute difference, -0.63% [95% CI, -1.20% to -0.06%]; HR, 0.46 [95% CI, 0.23-0.94]). CONCLUSIONS AND RELEVANCE: In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months of DAPT for the net clinical benefit with a numerical increase in cardiovascular events despite reduction in bleeding events. The directionally different efficacy and safety outcomes indicate the need for further clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02619760 and NCT03462498.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamacardio.2021.5244

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 325

Metadata

Authors
Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., Tatsushima, S., Watanabe, H., Ohya, M., Tokuyama, H., Tada, T., Sakamoto, H., Mori, H., Suzuki, H., Nishikura, T., Wakabayashi, K., Hibi, K., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., STOPDAPT-2 ACS Investigators, Kozuma, K., Hanaoka, K., Tezuka, S., Fujino, Y., Kato, R., Kitamura, M., Tsumori, M., Hanazawa, M., Yamauchi, M., Yamazaki, I., Hirokami, M., Makiguchi, N., Nozaki, Y., Tomita, H., Yagi, M., Komaru, T., Higuchi, M., Isshiki, T., Kodama, T., Tosaka, A., Takamisawa, I., Tanaka, H., Hata, Y., Kato, R., Akashi, Y., Yumoto, K., Tsukahara, K., Ako, J., Onishi, Y., Uzui, H., Noda, T., Morishima, I., Yamada, M., Yoshida, R., Suzuki, S., Maeda, T., Tanigawa, T., Kaitani, K., Matsuoka, S., Akao, M., Yokomatsu, T., Inoko, M., Inada, T., Morita, T., Nakazawa, G., Ishihara, S., Kinoshita, M., Kusuyama, T., Togi, K., Tamura, T., Akasaka, T., Tabuchi, I., Kihara, Y., Ueda, H., Katayama, Y., Wakeyama, T., Kaneko, T., Wakatsuki, T., Kishi, K., Doi, M., Okayama, H., Suematsu, N., Inoue, S., Natsuaki, M., Tsujita, K., Sakamoto, T., Kurokawa, H., Kashima, K., & Uehara, H.
Venue
JAMA Cardiology
Published
2022-04-01
Volume
7
Issue
4
Pages
407
ISSN
2380-6583 (ISSN-L)
OpenAlex
W4214943375
Cited by
325
References
31
FWCI
42.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamacardio.2021.5244
The paper
Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., Tatsushima, S., Watanabe, H., Ohya, M., Tokuyama, H., Tada, T., Sakamoto, H., Mori, H., Suzuki, H., Nishikura, T., . . . Uehara, H. (2022). Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2021.5244

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.